In additional, C2 shows higher STAG2 mutant rates, which is reportedly correlated with poor prognosis in BLCA [49]; STAG2 has also been shown to regulate the cell cycle progression of bladder cancer cells [50], suggesting that the C2 group may respond to chemotherapy. This evidence concerns the gene STAG2 and urinary bladder carcinoma.